Country: Canada
Language: English
Source: Health Canada
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE); METFORMIN HYDROCHLORIDE
APOTEX INC
A10BD07
METFORMIN AND SITAGLIPTIN
100MG; 1000MG
TABLET (EXTENDED-RELEASE)
SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 100MG; METFORMIN HYDROCHLORIDE 1000MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0252656004; AHFS:
APPROVED
2022-10-24
APO-SITAGLIPTIN/METFORMIN XR Page 1 of 75 (Sitagliptin and metformin hydrochloride modified-release tablets) PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-SITAGLIPTIN/METFORMIN XR Sitagliptin (as sitagliptin phosphate monohydrate) and metformin hydrochloride modified-release Tablets, 50 mg/500 mg, 50 mg/1000 mg, and 100 mg/1000 mg, Oral Combinations of oral blood glucose lowering drugs APOTEX INC. Date of Initial Authorization 150 Signet Drive October 6, 2020 Toronto, Ontario Date of Revision M9L 1T9 February 25, 2022 Submission Control No: 257179 APO-SITAGLIPTIN/METFORMIN XR Page 2 of 75 (Sitagliptin and metformin hydrochloride modified-release tablets) RECENT MAJOR LABEL CHANGES 1 Indications 02/2022 4 Dosage and Administration 02/2022 7 Warnings and Precautions 02/2022 Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................. 4 1 INDICATIONS...................................................................................................... 4 1.1 Pediatrics...................................................................................................... 4 1.2 Geriatrics ...................................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.............................................. 5 4 DOSAGE AND ADMINISTRATION ...................................................................... 6 4.1 Dosing Considerations .................................................................................. 6 4.2 Recommended Dose and Dosage Adjustment ............................................... 6 4.4 Administration .............................................................. Read the complete document